KA
AVXL icon

Kerrisdale Advisers’s Anavex Life Sciences AVXL Stock Holding History

Kerrisdale Advisers’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-39,897
Closed -$342K – 83
2023
Q1 		$342K Buy
+39,897
New +$398K 0.1% 80

Other funds holding AVXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
NL
NWAM LLC Mercer Island, Washington $1.74B AUM 32.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Kerrisdale Advisers's AVXL Position: Q2 2023 in Review

Kerrisdale Advisers sold out of Anavex Life Sciences (AVXL) in Q2 2023, closing a stake of 39,897 shares — an estimated $342K sold.

Kerrisdale Advisers first reported a position in AVXL in Q1 2023 and held it in 1 quarter. The position peaked at $342K in Q1 2023. 144 funds tracked by Wall St. Rank hold AVXL as of Q2 2023.

  • Kerrisdale Advisers reported no remaining Anavex Life Sciences position as of Q2 2023 after selling out during the quarter.
  • Kerrisdale Advisers sold 39,897 Anavex Life Sciences shares in Q2 2023, an estimated $342K.
  • Kerrisdale Advisers first reported a position in Anavex Life Sciences in Q1 2023 and held it in 1 quarter.
  • Kerrisdale Advisers's Anavex Life Sciences position peaked at $342K in Q1 2023.
  • 144 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2023.

Based on Kerrisdale Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.